|
US5378696A
(en)
*
|
1990-09-19 |
1995-01-03 |
American Home Products Corporation |
Rapamycin esters
|
|
US5177203A
(en)
*
|
1992-03-05 |
1993-01-05 |
American Home Products Corporation |
Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
|
|
US5260299A
(en)
*
|
1992-03-05 |
1993-11-09 |
American Home Products Corporation |
Rapamycin 42-sulfonates and 42-(N-Carboalkoxy)Sulfamates Useful as Immunosuppressive Agents
|
|
US5256790A
(en)
*
|
1992-08-13 |
1993-10-26 |
American Home Products Corporation |
27-hydroxyrapamycin and derivatives thereof
|
|
US5480988A
(en)
*
|
1992-10-13 |
1996-01-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
|
US5480989A
(en)
*
|
1992-10-13 |
1996-01-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
|
US5434260A
(en)
*
|
1992-10-13 |
1995-07-18 |
American Home Products Corporation |
Carbamates of rapamycin
|
|
US5489680A
(en)
*
|
1992-10-13 |
1996-02-06 |
American Home Products Corporation |
Carbamates of rapamycin
|
|
US5349060A
(en)
*
|
1993-01-07 |
1994-09-20 |
American Home Products Corporation |
Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
|
|
US5252579A
(en)
*
|
1993-02-16 |
1993-10-12 |
American Home Products Corporation |
Macrocyclic immunomodulators
|
|
GB9307491D0
(en)
|
1993-04-08 |
1993-06-02 |
Sandoz Ltd |
Organic compounds
|
|
USRE40596E1
(en)
*
|
1993-04-08 |
2008-12-02 |
Novartis Ag |
Rapamycin assay
|
|
US7279561B1
(en)
*
|
1993-04-23 |
2007-10-09 |
Wyeth |
Anti-rapamycin monoclonal antibodies
|
|
EP1181938B1
(en)
|
1993-04-23 |
2007-11-14 |
Wyeth |
Rapamycin conjugates and antibodies
|
|
AU6711994A
(en)
*
|
1993-04-23 |
1994-11-21 |
American Home Products Corporation |
Rapamycin conjugates and antibodies
|
|
US5504091A
(en)
*
|
1993-04-23 |
1996-04-02 |
American Home Products Corporation |
Biotin esters of rapamycin
|
|
US5387680A
(en)
*
|
1993-08-10 |
1995-02-07 |
American Home Products Corporation |
C-22 ring stabilized rapamycin derivatives
|
|
US5391730A
(en)
*
|
1993-10-08 |
1995-02-21 |
American Home Products Corporation |
Phosphorylcarbamates of rapamycin and oxime derivatives thereof
|
|
US5373014A
(en)
*
|
1993-10-08 |
1994-12-13 |
American Home Products Corporation |
Rapamycin oximes
|
|
US5378836A
(en)
*
|
1993-10-08 |
1995-01-03 |
American Home Products Corporation |
Rapamycin oximes and hydrazones
|
|
CA2175215C
(en)
*
|
1993-11-19 |
2008-06-03 |
Yat Sun Or |
Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
|
|
US5527907A
(en)
*
|
1993-11-19 |
1996-06-18 |
Abbott Laboratories |
Macrolide immunomodulators
|
|
US5385908A
(en)
*
|
1993-11-22 |
1995-01-31 |
American Home Products Corporation |
Hindered esters of rapamycin
|
|
US5385909A
(en)
*
|
1993-11-22 |
1995-01-31 |
American Home Products Corporation |
Heterocyclic esters of rapamycin
|
|
US5385910A
(en)
*
|
1993-11-22 |
1995-01-31 |
American Home Products Corporation |
Gem-distributed esters of rapamycin
|
|
US5389639A
(en)
*
|
1993-12-29 |
1995-02-14 |
American Home Products Company |
Amino alkanoic esters of rapamycin
|
|
US5525610A
(en)
*
|
1994-03-31 |
1996-06-11 |
American Home Products Corporation |
42-Epi-rapamycin and pharmaceutical compositions thereof
|
|
US5362718A
(en)
|
1994-04-18 |
1994-11-08 |
American Home Products Corporation |
Rapamycin hydroxyesters
|
|
US5463048A
(en)
*
|
1994-06-14 |
1995-10-31 |
American Home Products Corporation |
Rapamycin amidino carbamates
|
|
US5491231A
(en)
*
|
1994-11-28 |
1996-02-13 |
American Home Products Corporation |
Hindered N-oxide esters of rapamycin
|
|
US5563145A
(en)
*
|
1994-12-07 |
1996-10-08 |
American Home Products Corporation |
Rapamycin 42-oximes and hydroxylamines
|
|
US6124453A
(en)
*
|
1995-07-04 |
2000-09-26 |
Novartis Ag |
Macrolides
|
|
US5780462A
(en)
*
|
1995-12-27 |
1998-07-14 |
American Home Products Corporation |
Water soluble rapamycin esters
|
|
US5922730A
(en)
*
|
1996-09-09 |
1999-07-13 |
American Home Products Corporation |
Alkylated rapamycin derivatives
|
|
US6709873B1
(en)
|
1997-04-09 |
2004-03-23 |
Isodiagnostika Inc. |
Method for production of antibodies to specific sites of rapamycin
|
|
US20030129215A1
(en)
*
|
1998-09-24 |
2003-07-10 |
T-Ram, Inc. |
Medical devices containing rapamycin analogs
|
|
US7399480B2
(en)
|
1997-09-26 |
2008-07-15 |
Abbott Laboratories |
Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
|
|
US6015815A
(en)
|
1997-09-26 |
2000-01-18 |
Abbott Laboratories |
Tetrazole-containing rapamycin analogs with shortened half-lives
|
|
US6890546B2
(en)
*
|
1998-09-24 |
2005-05-10 |
Abbott Laboratories |
Medical devices containing rapamycin analogs
|
|
US20060198867A1
(en)
*
|
1997-09-25 |
2006-09-07 |
Abbott Laboratories, Inc. |
Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
|
|
US8257726B2
(en)
*
|
1997-09-26 |
2012-09-04 |
Abbott Laboratories |
Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
|
|
US7378105B2
(en)
*
|
1997-09-26 |
2008-05-27 |
Abbott Laboratories |
Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens
|
|
US7357942B2
(en)
*
|
1997-09-26 |
2008-04-15 |
Abbott Laboratories |
Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
|
|
US8394398B2
(en)
*
|
1997-09-26 |
2013-03-12 |
Abbott Laboratories |
Methods of administering rapamycin analogs with anti-inflammatories using medical devices
|
|
US8057816B2
(en)
*
|
1997-09-26 |
2011-11-15 |
Abbott Laboratories |
Compositions and methods of administering paclitaxel with other drugs using medical devices
|
|
US8257725B2
(en)
*
|
1997-09-26 |
2012-09-04 |
Abbott Laboratories |
Delivery of highly lipophilic agents via medical devices
|
|
US6015809A
(en)
*
|
1998-08-17 |
2000-01-18 |
American Home Products Corporation |
Photocyclized rapamycin
|
|
US7960405B2
(en)
*
|
1998-09-24 |
2011-06-14 |
Abbott Laboratories |
Compounds and methods for treatment and prevention of diseases
|
|
US20060240070A1
(en)
*
|
1998-09-24 |
2006-10-26 |
Cromack Keith R |
Delivery of highly lipophilic agents via medical devices
|
|
US7455853B2
(en)
*
|
1998-09-24 |
2008-11-25 |
Abbott Cardiovascular Systems Inc. |
Medical devices containing rapamycin analogs
|
|
US8257724B2
(en)
*
|
1998-09-24 |
2012-09-04 |
Abbott Laboratories |
Delivery of highly lipophilic agents via medical devices
|
|
US6331547B1
(en)
|
1999-08-18 |
2001-12-18 |
American Home Products Corporation |
Water soluble SDZ RAD esters
|
|
US6277983B1
(en)
|
2000-09-27 |
2001-08-21 |
American Home Products Corporation |
Regioselective synthesis of rapamycin derivatives
|
|
US6670355B2
(en)
|
2000-06-16 |
2003-12-30 |
Wyeth |
Method of treating cardiovascular disease
|
|
JP2004507465A
(ja)
|
2000-08-11 |
2004-03-11 |
ワイス |
エストロゲン受容体陽性癌腫の治療方法
|
|
AU2001290841A1
(en)
|
2000-09-19 |
2002-04-02 |
American Home Products Corporation |
Water soluble rapamycin esters
|
|
US6399625B1
(en)
|
2000-09-27 |
2002-06-04 |
Wyeth |
1-oxorapamycins
|
|
US6399626B1
(en)
|
2000-10-02 |
2002-06-04 |
Wyeth |
Hydroxyesters of 7-desmethylrapamycin
|
|
US6440991B1
(en)
|
2000-10-02 |
2002-08-27 |
Wyeth |
Ethers of 7-desmethlrapamycin
|
|
US20040018228A1
(en)
*
|
2000-11-06 |
2004-01-29 |
Afmedica, Inc. |
Compositions and methods for reducing scar tissue formation
|
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US20080145402A1
(en)
*
|
2001-09-10 |
2008-06-19 |
Abbott Cardiovascular Systems Inc. |
Medical Devices Containing Rapamycin Analogs
|
|
CA2472341C
(en)
|
2002-02-01 |
2011-06-21 |
Ariad Gene Therapeutics, Inc. |
Phosphorus-containing compounds & uses thereof
|
|
TWI307277B
(en)
|
2002-07-30 |
2009-03-11 |
Wyeth Corp |
Parenteral formulations
|
|
AU2003218077B2
(en)
|
2002-09-06 |
2009-10-08 |
Abbott Laboratories |
Medical device having hydration inhibitor
|
|
US7485706B2
(en)
*
|
2003-07-30 |
2009-02-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Neurodegenerative protein aggregation inhibition methods and compounds
|
|
CN1882338A
(zh)
*
|
2003-09-18 |
2006-12-20 |
马库赛特公司 |
经巩膜递送
|
|
US7349971B2
(en)
*
|
2004-02-05 |
2008-03-25 |
Scenera Technologies, Llc |
System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information
|
|
US8431145B2
(en)
|
2004-03-19 |
2013-04-30 |
Abbott Laboratories |
Multiple drug delivery from a balloon and a prosthesis
|
|
US20070027523A1
(en)
*
|
2004-03-19 |
2007-02-01 |
Toner John L |
Method of treating vascular disease at a bifurcated vessel using coated balloon
|
|
US20100030183A1
(en)
*
|
2004-03-19 |
2010-02-04 |
Toner John L |
Method of treating vascular disease at a bifurcated vessel using a coated balloon
|
|
CA2559747C
(en)
*
|
2004-03-19 |
2013-12-31 |
Abbott Laboratories |
Multiple drug delivery from a balloon and a prosthesis
|
|
BRPI0509810A
(pt)
*
|
2004-04-14 |
2007-09-18 |
Wyeth Corp |
método para a sìntese regioespecìfica de um 42-hemiéster de rapamicina ou um 32-hemiéster de fk-506 com um ácido dicarboxìlico, 42-hemiéster de rapamicina regioespecìfica, anticorpo de rapamicina, produto, e, 32-hemiéster de fk506 regioespecìfico
|
|
CA2562164A1
(en)
*
|
2004-04-27 |
2005-11-10 |
Wyeth |
Labeling of rapamycin using rapamycin-specific methylases
|
|
US8313763B2
(en)
*
|
2004-10-04 |
2012-11-20 |
Tolmar Therapeutics, Inc. |
Sustained delivery formulations of rapamycin compounds
|
|
MX2007003789A
(es)
*
|
2004-10-04 |
2007-07-20 |
Qlt Usa Inc |
Suministro ocular de formulaciones polimericas para suministro.
|
|
AU2005302004A1
(en)
*
|
2004-10-28 |
2006-05-11 |
Wyeth |
Use of an mTOR inhibitor in treatment of uterine leiomyoma
|
|
US8663639B2
(en)
*
|
2005-02-09 |
2014-03-04 |
Santen Pharmaceutical Co., Ltd. |
Formulations for treating ocular diseases and conditions
|
|
JP4974903B2
(ja)
*
|
2005-02-09 |
2012-07-11 |
参天製薬株式会社 |
疾患または状態を処置するための液体処方物
|
|
GB0503936D0
(en)
|
2005-02-25 |
2005-04-06 |
San Raffaele Centro Fond |
Method
|
|
US20100047338A1
(en)
|
2008-03-14 |
2010-02-25 |
Angela Brodie |
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
|
|
WO2006102378A2
(en)
*
|
2005-03-21 |
2006-09-28 |
Macusight, Inc. |
Drug delivery systems for treatment of diseases or conditions
|
|
EP1868663B1
(en)
*
|
2005-03-23 |
2011-11-16 |
Abbott Laboratories |
Delivery of highly lipophilic agents via medical devices
|
|
WO2007032777A2
(en)
|
2005-03-23 |
2007-03-22 |
Abbott Laboratories |
Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
|
|
JP5740076B2
(ja)
|
2005-07-25 |
2015-06-24 |
エマージェント・プロダクト・ディベロップメント・シアトル・エルエルシー |
Cd37特異的及びcd20特異的結合分子を用いたb細胞の減少
|
|
JP2009514870A
(ja)
|
2005-11-04 |
2009-04-09 |
ワイス |
mTORインヒビター、ハーセプチン、および/またはHKI−272の抗悪性腫瘍性組み合わせ
|
|
US7700614B2
(en)
|
2005-12-14 |
2010-04-20 |
Abbott Laboratories |
One pot synthesis of tetrazole derivatives of rapamycin
|
|
JP5528708B2
(ja)
*
|
2006-02-09 |
2014-06-25 |
参天製薬株式会社 |
安定な製剤ならびにそれらを調製および使用する方法
|
|
US20070203169A1
(en)
*
|
2006-02-28 |
2007-08-30 |
Zhao Jonathon Z |
Isomers and 42-epimers of rapamycin ester analogs, methods of making and using the same
|
|
US7678901B2
(en)
*
|
2006-02-28 |
2010-03-16 |
Wyeth |
Rapamycin analogs containing an antioxidant moiety
|
|
US7622477B2
(en)
*
|
2006-02-28 |
2009-11-24 |
Cordis Corporation |
Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
|
|
JP5506378B2
(ja)
|
2006-03-23 |
2014-05-28 |
参天製薬株式会社 |
血管透過性に関連する疾患または病気のための製剤および方法
|
|
US7883855B2
(en)
*
|
2006-07-21 |
2011-02-08 |
Abbott Laboratories |
Immunosuppressant drug extraction reagent for immunoassays
|
|
US20080051691A1
(en)
*
|
2006-08-28 |
2008-02-28 |
Wyeth |
Implantable shunt or catheter enabling gradual delivery of therapeutic agents
|
|
US20080276935A1
(en)
|
2006-11-20 |
2008-11-13 |
Lixiao Wang |
Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
|
|
US8998846B2
(en)
|
2006-11-20 |
2015-04-07 |
Lutonix, Inc. |
Drug releasing coatings for balloon catheters
|
|
US8414525B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
|
US20080175887A1
(en)
|
2006-11-20 |
2008-07-24 |
Lixiao Wang |
Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
|
|
US8414910B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
|
US9737640B2
(en)
|
2006-11-20 |
2017-08-22 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
|
US9700704B2
(en)
|
2006-11-20 |
2017-07-11 |
Lutonix, Inc. |
Drug releasing coatings for balloon catheters
|
|
US8414526B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
|
|
US8425459B2
(en)
|
2006-11-20 |
2013-04-23 |
Lutonix, Inc. |
Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
|
|
TW200901989A
(en)
|
2007-04-10 |
2009-01-16 |
Wyeth Corp |
Anti-tumor activity of CCI-779 in papillary renal cell cancer
|
|
JP2008305262A
(ja)
*
|
2007-06-08 |
2008-12-18 |
Konica Minolta Business Technologies Inc |
サーバ及びシンクライアント環境でのプリンタ紹介方法
|
|
JP2010532764A
(ja)
*
|
2007-07-06 |
2010-10-14 |
トゥルビオン・ファーマシューティカルズ・インコーポレーテッド |
C末端に配置された特異的結合性ドメインを有する結合性ペプチド
|
|
EP2232264B1
(en)
|
2007-12-19 |
2015-12-02 |
Abbott Laboratories |
Immunosuppressant drug extraction reagent for immunoassays
|
|
AU2009225434B2
(en)
*
|
2008-03-21 |
2014-05-22 |
The University Of Chicago |
Treatment with opioid antagonists and mTOR inhibitors
|
|
CN105198997B
(zh)
*
|
2008-04-11 |
2018-08-31 |
阿普拜佛研发有限责任公司 |
Cd37免疫治疗剂及其与双功能化学治疗剂的联合
|
|
WO2010024898A2
(en)
|
2008-08-29 |
2010-03-04 |
Lutonix, Inc. |
Methods and apparatuses for coating balloon catheters
|
|
ES2645692T3
(es)
|
2008-11-11 |
2017-12-07 |
The Board Of Regents,The University Of Texas System |
Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
|
|
WO2010091306A1
(en)
|
2009-02-05 |
2010-08-12 |
Tokai Pharmaceuticals |
Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
|
|
CA2777128A1
(en)
|
2009-10-30 |
2011-05-05 |
Ariad Pharmaceuticals, Inc. |
Methods and compositions for treating cancer
|
|
WO2015161139A1
(en)
|
2014-04-16 |
2015-10-22 |
Rapamycin Holdings, Llc |
Oral rapamycin preparation and use for stomatitis
|
|
US9283211B1
(en)
|
2009-11-11 |
2016-03-15 |
Rapamycin Holdings, Llc |
Oral rapamycin preparation and use for stomatitis
|
|
US20110144577A1
(en)
*
|
2009-12-11 |
2011-06-16 |
John Stankus |
Hydrophilic coatings with tunable composition for drug coated balloon
|
|
US8951595B2
(en)
*
|
2009-12-11 |
2015-02-10 |
Abbott Cardiovascular Systems Inc. |
Coatings with tunable molecular architecture for drug-coated balloon
|
|
US8480620B2
(en)
*
|
2009-12-11 |
2013-07-09 |
Abbott Cardiovascular Systems Inc. |
Coatings with tunable solubility profile for drug-coated balloon
|
|
CA2792258A1
(en)
|
2010-03-05 |
2011-09-09 |
President And Fellows Of Harvard College |
Induced dendritic cell compositions and uses thereof
|
|
CN102844049B
(zh)
|
2010-04-27 |
2016-06-01 |
罗切格利卡特公司 |
无岩藻糖基化CD20抗体与mTOR抑制剂的联合疗法
|
|
JP6170840B2
(ja)
|
2011-03-11 |
2017-07-26 |
ベス イスラエル デアコネス メディカル センター インコーポレイテッド |
抗cd40抗体及びその使用
|
|
US9896730B2
(en)
|
2011-04-25 |
2018-02-20 |
OSI Pharmaceuticals, LLC |
Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
|
|
EP2532740A1
(en)
|
2011-06-11 |
2012-12-12 |
Michael Schmück |
Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
|
|
WO2013013708A1
(en)
|
2011-07-26 |
2013-01-31 |
Fundació Institut D'investigació Biomèdica De Bellvitge |
Treatment of acute rejection in renal transplant
|
|
CN103705925B
(zh)
|
2012-09-29 |
2018-03-30 |
段磊 |
抑制PI3K/AKT/mTOR信号通路的药物组合
|
|
US9750728B2
(en)
|
2012-09-29 |
2017-09-05 |
Targeted Therapeutics, Llc |
Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
|
|
WO2014059295A1
(en)
|
2012-10-12 |
2014-04-17 |
The Board Of Regents Of The University Of Texas System |
Use of mtor inhibitors to treat vascular cognitive impairment
|
|
WO2014068070A1
(en)
|
2012-10-31 |
2014-05-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preventing antiphospholipid syndrome (aps)
|
|
WO2014160328A1
(en)
|
2013-03-13 |
2014-10-02 |
The Board Of Regents Of The University Of Texas System |
Mtor inhibitors for prevention of intestinal polyp growth
|
|
AU2014236135A1
(en)
|
2013-03-14 |
2015-09-10 |
Thomas Jefferson University |
Androgen receptor down-regulating agents and uses thereof
|
|
KR20160058774A
(ko)
|
2013-08-12 |
2016-05-25 |
토카이 파마슈티컬, 아이엔씨. |
안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
|
|
AU2014373683B2
(en)
|
2013-12-31 |
2020-05-07 |
Rapamycin Holdings, Llc |
Oral rapamycin nanoparticle preparations and use
|
|
US9700544B2
(en)
|
2013-12-31 |
2017-07-11 |
Neal K Vail |
Oral rapamycin nanoparticle preparations
|
|
AU2015237200A1
(en)
|
2014-03-27 |
2016-10-06 |
The Brigham And Women's Hospital, Inc. |
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
|
|
JP2017518307A
(ja)
|
2014-06-02 |
2017-07-06 |
チルドレンズ メディカル センター コーポレーション |
免疫調節のための方法および組成物
|
|
JP6692798B2
(ja)
|
2014-09-11 |
2020-05-13 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア |
mTORC1阻害剤
|
|
WO2017029391A1
(en)
|
2015-08-20 |
2017-02-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating cancer
|
|
EP3906943A1
(en)
|
2015-09-04 |
2021-11-10 |
Primatope Therapeutics Inc. |
Humanized anti-cd40 antibodies and uses thereof
|
|
WO2017181115A1
(en)
|
2016-04-14 |
2017-10-19 |
Spinnaker Biosciences, Inc. |
Porous silicon materials comprising a metal silicate for delivery of therapeutic agents
|
|
KR20190025635A
(ko)
|
2016-06-30 |
2019-03-11 |
듀렉트 코퍼레이션 |
데포 제형
|
|
US10682340B2
(en)
|
2016-06-30 |
2020-06-16 |
Durect Corporation |
Depot formulations
|
|
EA201990127A1
(ru)
|
2016-12-30 |
2020-08-18 |
Дьюрект Корпорейшн |
Депо-препарат
|
|
EP3848065B1
(en)
|
2017-05-15 |
2023-07-26 |
C. R. Bard, Inc. |
Medical device with drug-eluting coating and intermediate layer
|
|
CN108948046B
(zh)
*
|
2017-05-20 |
2020-11-10 |
鲁南制药集团股份有限公司 |
一种替西罗莫司的中间体及其制备方法
|
|
WO2019002168A1
(en)
|
2017-06-26 |
2019-01-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING OLMSTED SYNDROME
|
|
US20210147801A1
(en)
|
2017-07-13 |
2021-05-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for increasing expansion and immunosuppressive capacity of a population of cd8+cd45rclow/- tregs
|
|
MX2020011564A
(es)
|
2018-05-01 |
2021-01-29 |
Revolution Medicines Inc |
Analogos de rapamicina unidos a c26 como inhibidores de mtor.
|
|
AU2019262978B2
(en)
|
2018-05-01 |
2023-07-13 |
Revolution Medicines, Inc. |
C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
|
|
CA3107349A1
(en)
|
2018-07-23 |
2020-01-30 |
Enclear Therapies, Inc. |
Methods of treating neurological disorders
|
|
WO2020023418A1
(en)
|
2018-07-23 |
2020-01-30 |
Enclear Therapies, Inc. |
Methods of treating neurological disorders
|
|
WO2020053125A1
(en)
|
2018-09-10 |
2020-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of neurofibromatosis
|
|
EP3880266B1
(en)
|
2018-11-14 |
2025-05-07 |
Lutonix, Inc. |
Medical device with drug-eluting coating on modified device surface
|
|
WO2020209828A1
(en)
|
2019-04-08 |
2020-10-15 |
Bard Peripheral Vascular, Inc. |
Medical device with drug-eluting coating on modified device surface
|
|
JP2022526671A
(ja)
|
2019-04-11 |
2022-05-25 |
エンクリアー セラピーズ, インク. |
脳脊髄液の改善の方法ならびにそのためのデバイスおよびシステム
|
|
AU2021355470A1
(en)
|
2020-09-29 |
2023-06-01 |
Enclear Therapies, Inc. |
Subarachnoid fluid management method and system
|
|
US20240382628A1
(en)
|
2021-07-15 |
2024-11-21 |
President And Fellows Of Harvard College |
Compositions and methods relating to cells with adhered particles
|
|
CA3256390A1
(en)
|
2022-05-25 |
2023-11-30 |
Revolution Medicines, Inc. |
CANCER TREATMENT METHODS USING AN MTOR INHIBITOR
|
|
WO2024008799A1
(en)
|
2022-07-06 |
2024-01-11 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of proliferative glomerulonephritis
|
|
EP4565217A1
(en)
|
2022-08-04 |
2025-06-11 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of lymphoproliferative disorders
|